AveXis Inc logo

AVXS - AveXis Inc Share Price

$217.83 0.0  0.0%

Last Trade - 14/05/18

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 6623
Bullish
Bearish
Unlock AVXS Revenue
Momentum
Relative Strength (%)
1m -0.85%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2012 2013 2014 2015 2016 2017 2018E 2019E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 0.80 80.9
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2018, AveXis Increvenues was not reported. Net loss increased from $29.7Mto $222.1M. Higher net loss reflects Research anddevelopment - Balancing increase from $18.3M to $192.7M(expense), General and administrative - Balancing increasefrom $6.9M to $17.5M (expense), Stock-based Compensation inR&D increase from $2M to $7M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AVXS Revenue Unlock AVXS Revenue

Net Income

AVXS Net Income Unlock AVXS Revenue

Normalised EPS

AVXS Normalised EPS Unlock AVXS Revenue

PE Ratio Range

AVXS PE Ratio Range Unlock AVXS Revenue

Dividend Yield Range

AVXS Dividend Yield Range Unlock AVXS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AVXS EPS Forecasts Unlock AVXS Revenue
Profile Summary

AveXis, Inc. is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company's product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either have experienced a deletion of their SMN1 genes, which prevents them from producing adequate levels of functional SMN protein, or carry a mutation in their SMN1 gene. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels.

Directors
Last Annual December 31st, 2017
Last Interim March 31st, 2018
Incorporated March 10, 2010
Public Since February 10, 2016
No. of Shareholders: 18
No. of Employees: 219
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Global Select Market
Shares in Issue 36,816,476
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AVXS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AVXS
Upcoming Events for AVXS
Frequently Asked Questions for AveXis Inc
What is the AveXis Inc share price?

As of 14/05/18, shares in AveXis Inc are trading at $217.83, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the AveXis Inc share price performed this year?

Shares in AveXis Inc are currently trading at $217.83 and the price has moved by 0.184k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the AveXis Inc price has moved by 0.143k% over the past year.

What are the analyst and broker recommendations for AveXis Inc?

Of the analysts with advisory recommendations for AveXis Inc, there are there are currently 1 "buy" , 13 "hold" and 0 "sell" recommendations. The overall consensus recommendation for AveXis Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will AveXis Inc next release its financial results?

AveXis Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2019-03-31
What is the AveXis Inc dividend yield?

AveXis Inc does not currently pay a dividend.

Does AveXis Inc pay a dividend?

AveXis Inc does not currently pay a dividend.

When does AveXis Inc next pay dividends?

AveXis Inc does not currently pay a dividend.

How do I buy AveXis Inc shares?

To buy shares in AveXis Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of AveXis Inc?

Shares in AveXis Inc are currently trading at $217.83, giving the company a market capitalisation of £n/a.

Where are AveXis Inc shares listed? Where are AveXis Inc shares listed?

Here are the trading details for AveXis Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: AVXS
What kind of share is AveXis Inc?

We were not able to load our ranking data for AveXis Inc

Is there a AveXis Inc share price forecast 2021?

We were not able to load any forecast data for AveXis Inc.

How can I tell whether the AveXis Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AveXis Inc. Over the past six months, the relative strength of its shares against the market has been 91.53%. At the current price of $217.83, shares in AveXis Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the AveXis Inc PE Ratio?

We were not able to find PE ratio data for AveXis Inc.

Who are the key directors of AveXis Inc?

We were unable to find the directors for AveXis Inc.

Who are the major shareholders of AveXis Inc?

Here are the top five shareholders of AveXis Inc based on the size of their shareholding:

Similar to AVXS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.